Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sitagliptin

FDA-approved product (tablet, oral), marketed as Zituvio, Brynovin, Januvia and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Sitagliptin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Hyperlipidemia
  • Myocardial infarction
  • Stroke
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dipeptidyl peptidase 4 (dpp-4) inhibitors
FDA pharmacologic class
Dipeptidyl Peptidase 4 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sitagliptin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sitagliptin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes

    NCT01624116 · start 2011-08

    Registered record
    Registry ID
    NCT01624116
    Conditions
    Diabetes, Type 2
    Interventions
    Acarbose; Diet and lifestyle; Metformin; Metformin/ Glimepride; Metformin/Sitagliptin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-08
    Completion
    2011-09
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes, Type 2
    InterventionAcarbose; Diet and lifestyle; Metformin; Metformin/ Glimepride +1 more
    PhaseNot applicable
    Registry statusCompleted

  • JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients

    NCT01269996 · start 2011-05

    Registered record
    Registry ID
    NCT01269996
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Janumet, Lantus; metformin, gliclazide, protaphane
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-05
    Completion
    2015-02
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionJanumet, Lantus; metformin, gliclazide, protaphane
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)

    NCT01076088 · start 2010-11-15

    Registered record
    Registry ID
    NCT01076088
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Sitagliptin 50 mg; Metformin 500 mg; Sitagliptin 100 mg; Placebo; Metformin 850 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-11-15
    Completion
    2012-12-24
    Enrolment
    744

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionSitagliptin 50 mg; Metformin 500 mg; Sitagliptin 100 mg; Placebo +1 more
    PhasePhase 3
    Registry statusCompleted

  • Changes in Bone Turnover With Increased Incretin Hormone Exposure

    NCT01374568 · start 2010-07

    Registered record
    Registry ID
    NCT01374568
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    sitagliptin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-07
    Completion
    2015-09
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    Interventionsitagliptin; Placebo
    PhasePhase 4
    Registry statusTerminated

  • Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV

    NCT01093651 · start 2010-06

    Registered record
    Registry ID
    NCT01093651
    Conditions
    Diabetes; Insulin Resistance
    Interventions
    Sitagliptin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2010-06
    Completion
    2012-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Insulin Resistance
    InterventionSitagliptin; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

    NCT01106690 · start 2010-06

    Registered record
    Registry ID
    NCT01106690
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Placebo; Canagliflozin; Sitagliptin; Metformin; Pioglitazone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-06
    Completion
    2012-07
    Enrolment
    344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionPlacebo; Canagliflozin; Sitagliptin; Metformin +1 more
    PhasePhase 3
    Registry statusCompleted

  • The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

    NCT01081834 · start 2010-03

    Registered record
    Registry ID
    NCT01081834
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Canagliflozin; Placebo; Sitagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-03
    Completion
    2012-03
    Enrolment
    678

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionCanagliflozin; Placebo; Sitagliptin
    PhasePhase 3
    Registry statusCompleted

  • Effect of Sitagliptin on Endothelial Progenitor Cells

    NCT00968006 · start 2009-10

    Registered record
    Registry ID
    NCT00968006
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Sitagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-10
    Completion
    2010-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionSitagliptin
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial

    NCT00851903 · start 2009-06

    Registered record
    Registry ID
    NCT00851903
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Insulin Glargine; Sitagliptin; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-06
    Completion
    2011-09
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionInsulin Glargine; Sitagliptin; Metformin
    PhasePhase 3
    Registry statusCompleted

  • "Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients"

    NCT00881543 · start 2009-06

    Registered record
    Registry ID
    NCT00881543
    Conditions
    Diabetes Type 2
    Interventions
    Dipeptidyl Peptidase IV inhibitors
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-06
    Completion
    2011-10
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Type 2
    InterventionDipeptidyl Peptidase IV inhibitors
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

    NCT00838903 · start 2009-02

    Registered record
    Registry ID
    NCT00838903
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    albiglutide; sitagliptin; glimepiride; metformin; placebo albiglutide; placebo sitagliptin; placebo glimepiride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-02
    Completion
    2013-04
    Enrolment
    1,049

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    Interventionalbiglutide; sitagliptin; glimepiride; metformin +3 more
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

    NCT00676338 · start 2008-11

    Registered record
    Registry ID
    NCT00676338
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    exenatide once weekly; metformin; sitagliptin; pioglitazone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-11
    Completion
    2011-01
    Enrolment
    820

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    Interventionexenatide once weekly; metformin; sitagliptin; pioglitazone
    PhasePhase 3
    Registry statusCompleted

  • Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

    NCT00775684 · start 2008-10

    Registered record
    Registry ID
    NCT00775684
    Conditions
    Pre-diabetes; Type 2 Diabetes
    Interventions
    Exenatide; Sitagliptin; Glimepiride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-10
    Completion
    2012-11
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPre-diabetes; Type 2 Diabetes
    InterventionExenatide; Sitagliptin; Glimepiride
    PhaseNot applicable
    Registry statusCompleted

  • MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

    NCT00722371 · start 2008-09-05

    Registered record
    Registry ID
    NCT00722371
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Sitagliptin phosphate; Pioglitazone hydrochloride; Matching placebo to sitagliptin; Matching placebo to pioglitazone; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-09-05
    Completion
    2011-03-25
    Enrolment
    1,615

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionSitagliptin phosphate; Pioglitazone hydrochloride; Matching placebo to sitagliptin; Matching placebo to pioglitazone +1 more
    PhasePhase 3
    Registry statusCompleted

  • Sitagliptin Versus Sulphonylurea in Type 2 Diabetes During Ramadan

    NCT00766441 · start 2008-08

    Registered record
    Registry ID
    NCT00766441
    Conditions
    Diabetes; Hypoglycemia
    Interventions
    Sitagliptin; sulphonylurea
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2008-08
    Completion
    2009-10
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Hypoglycemia
    InterventionSitagliptin; sulphonylurea
    PhasePhase 4
    Registry statusTerminated